Skip to main content

Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders

Guest Editors:
Professor Charlotte Teunissen, PhD, Amsterdam UMC, the Netherlands
Everard (Jort) Vijverberg, MD, PhD, Amsterdam UMC, the Netherlands

Submission Status: Closed   |   Submission Deadline: Closed


Alzheimer's Research & Therapy is calling for submissions to our Collection on Novel targets and therapies for Alzheimer's disease and other neurodegenerative disorders.

  1. Risk factors for cardiovascular disease, including elevated blood pressure, are known to increase risk of Alzheimer’s disease. There has been increasing awareness of the relationship between long-term blood pr...

    Authors: Sungjoo Lee, Si Eun Kim, Hyemin Jang, Jun Pyo Kim, Gyeongmo Sohn, Yu Hyun Park, Hongki Ham, Yuna Gu, Chae Jung Park, Hee Jin Kim, Duk L. Na, Kyunga Kim and Sang Won Seo
    Citation: Alzheimer's Research & Therapy 2024 16:125
  2. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) showed cognitive benefits from a multidomain lifestyle intervention in at-risk older people. The LipiDiDiet tria...

    Authors: Charlotta Thunborg, Rui Wang, Anna Rosenberg, Shireen Sindi, Pia Andersen, Sandrine Andrieu, Laus M. Broersen, Nicola Coley, Celine Couderc, Celine Z. Duval, Gerd Faxen-Irving, Göran Hagman, Merja Hallikainen, Krister Håkansson, Eija Kekkonen, Jenni Lehtisalo…
    Citation: Alzheimer's Research & Therapy 2024 16:118
  3. In Alzheimer’s disease (AD), microglia surround extracellular plaques and mount a sustained inflammatory response, contributing to the pathogenesis of the disease. Identifying approaches to specifically target...

    Authors: Caden M. Henningfield, Neelakshi Soni, Ryan W. Lee, Rishi Sharma, Jeffrey L. Cleland and Kim N. Green
    Citation: Alzheimer's Research & Therapy 2024 16:101
  4. Aberrant neuronal Sigma-1 receptor (Sig-1r)-mediated endoplasmic reticulum (ER)- mitochondria signaling plays a key role in the neuronal cytopathology of Alzheimer’s disease (AD). The natural psychedelic N, N-...

    Authors: Dan Cheng, Zhuo-Gui Lei, Kin Chu, Oi Jin Honey Lam, Chun Yuan Chiang and Zhang-Jin Zhang
    Citation: Alzheimer's Research & Therapy 2024 16:95
  5. The aggregation and spread of misfolded amyloid structured proteins, such as tau and α-synuclein, are key pathological features associated with neurodegenerative disorders, including Alzheimer’s and Parkinson’...

    Authors: Douglas M. Lopes, Jack A. Wells, Da Ma, Lauren Wallis, Daniel Park, Sophie K. Llewellyn, Zeshan Ahmed, Mark F. Lythgoe and Ian F. Harrison
    Citation: Alzheimer's Research & Therapy 2024 16:71
  6. Functional connectivity (FC) biomarkers play a crucial role in the early diagnosis and mechanistic study of Alzheimer’s disease (AD). However, the identification of effective FC biomarkers remains challenging....

    Authors: Ying Zhang, Le Xue, Shuoyan Zhang, Jiacheng Yang, Qi Zhang, Min Wang, Luyao Wang, Mingkai Zhang, Jiehui Jiang and Yunxia Li
    Citation: Alzheimer's Research & Therapy 2024 16:60
  7. Cardiovascular health has been associated with dementia onset, but little is known about the variation of such association by sex and age considering dementia subtypes. We assessed the role of sex and age in t...

    Authors: Anna Ponjoan, Jordi Blanch, Ester Fages-Masmiquel, Ruth Martí-Lluch, Lia Alves-Cabratosa, María del Mar Garcia-Gil, Gina Domínguez-Armengol, Francesc Ribas-Aulinas, Lluís Zacarías-Pons and Rafel Ramos
    Citation: Alzheimer's Research & Therapy 2024 16:58
  8. Studies have suggested that blood circulating phytosterols, plant-derived sterols analogous to cholesterol, were associated with blood lipid levels and the risk of Alzheimer’s disease (AD) and Parkinson’s dise...

    Authors: Xingzhi Guo, Jing Yu, Rui Wang, Ning Peng and Rui Li
    Citation: Alzheimer's Research & Therapy 2024 16:53
  9. GOIZ ZAINDU (“caring early” in Basque) is a pilot study to adapt the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) methodology to the Basque population and evalua...

    Authors: Mikel Tainta, Mirian Ecay-Torres, Maria de Arriba, Myriam Barandiaran, Ane Otaegui-Arrazola, Ane Iriondo, Maite Garcia-Sebastian, Ainara Estanga, Jon Saldias, Montserrat Clerigue, Alazne Gabilondo, Naia Ros, Justo Mugica, Aitziber Barandiaran, Francesca Mangialasche, Miia Kivipelto…
    Citation: Alzheimer's Research & Therapy 2024 16:44
  10. Effective, disease-modifying therapeutics for the treatment of Alzheimer’s disease (AD) remain a large unmet need. Extensive evidence suggests that amyloid beta (Aβ) is central to AD pathophysiology, and Aβ ol...

    Authors: Christopher H. van Dyck, Adam P. Mecca, Ryan S. O’Dell, Hugh H. Bartlett, Nina G. Diepenbrock, Yiyun Huang, Mary E. Hamby, Michael Grundman, Susan M. Catalano, Anthony O. Caggiano and Richard E. Carson
    Citation: Alzheimer's Research & Therapy 2024 16:20
  11. Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the initial...

    Authors: Jie Wang, Yingfang He, Xing Chen, Lin Huang, Junpeng Li, Zhiwen You, Qi Huang, Shuhua Ren, Kun He, Roger Schibli, Linjing Mu, Yihui Guan, Qihao Guo, Jun Zhao and Fang Xie
    Citation: Alzheimer's Research & Therapy 2024 16:9
  12. Recently, single-nucleus RNA-seq (snRNA-seq) analyses have revealed important cellular and functional features of Alzheimer's disease (AD), a prevalent neurodegenerative disease. However, our knowledge regardi...

    Authors: Andi Liu, Brisa S. Fernandes, Citu Citu and Zhongming Zhao
    Citation: Alzheimer's Research & Therapy 2024 16:3
  13. Alzheimer’s disease (AD) is characterized by cognitive dysfunction and amyloid plaques composed of the amyloid-beta peptide (Aβ). APOE is the greatest genetic risk for AD with APOE4 increasing risk up to ~ 15-fol...

    Authors: Ana C. Valencia-Olvera, Deebika Balu, Shreya Bellur, Thomas McNally, Yaseen Saleh, Don Pham, Shivesh Ghura, Jason York, Jan O. Johansson, Mary Jo LaDu and Leon Tai
    Citation: Alzheimer's Research & Therapy 2023 15:216
  14. NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, ...

    Authors: Saily Sosa, Giosmany Bringas, Nelky Urrutia, Ana Ivis Peñalver, Danay López, Evelio González, Ana Fernández, Zenaida Milagros Hernández, Ariel Viña, Yamile Peña, Juan Felipe Batista, Carmen Valenzuela, Kalet León, Tania Crombet, Teresita Rodríguez and Leslie Pérez
    Citation: Alzheimer's Research & Therapy 2023 15:215
  15. The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...

    Authors: Pablo Mohaupt, Jérôme Vialaret, Christophe Hirtz and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2023 15:170
  16. Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...

    Authors: Daniele Altomare, Alberto Benussi, Valentina Cantoni, Enrico Premi, Jasmine Rivolta, Chiara Cupidi, Alessandro Martorana, Emiliano Santarnecchi, Alessandro Padovani, Giacomo Koch and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2023 15:155
  17. Little is known about the associations of midlife- and late life-initiated walking with Alzheimer’s disease (AD)-related cognitive decline in humans. We aimed to investigate whether high-intensity, prolonged, ...

    Authors: Young Min Choe, Guk-Hee Suh, Boung Chul Lee, Ihn-Geun Choi, Hyun Soo Kim, Jong Wan Kim, Jaeuk Hwang, Dahyun Yi and Jee Wook Kim
    Citation: Alzheimer's Research & Therapy 2023 15:143

About the collection

The scientific field of neurodegenerative dementias has made significant progress over the last two decades. The diagnosis for these progressive neurodegenerative diseases is increasingly shifting from syndromal, based on signs and symptoms, to a biological construct based on the pathological hallmarks. For Alzheimer's disease (AD) it is amyloid β deposition, pathologic tau, neurodegeneration, and it is expected that analysis of alfa-synuclein (e.g. by aggregating assays) can contribute to an accurate diagnosis and to define progression and treatment effects. Furthermore, numerous genetic risk factors have been identified providing further insight into the pathways underpinning dementias.

Analogous to this significant progress in making an accurate diagnosis and a better understanding in dementia disorders, the drug development landscape for disease modifying therapies also grows. Especially in AD, amyloid-targeting therapies are now showing potential, while it is clear that multitarget interventions are probably needed to better silence these diseases. Moreover, drugs against targets that play a key role in several neurodegenerative diseases can be applied across diseases.